- Home
- UCAR vs RLMD Comparison
UCAR vs RLMD Comparison
Compare UCAR & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCAR
- RLMD
- Stock Information
- Founded
- UCAR 2013
- RLMD 2004
- Country
- UCAR China
- RLMD United States
- Employees
- UCAR N/A
- RLMD N/A
- Industry
- UCAR Retail-Auto Dealers and Gas Stations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- UCAR Consumer Discretionary
- RLMD Health Care
- Exchange
- UCAR Nasdaq
- RLMD Nasdaq
- Market Cap
- UCAR 10.6M
- RLMD 11.5M
- IPO Year
- UCAR 2023
- RLMD N/A
- Fundamental
- Price
- UCAR $3.00
- RLMD $0.42
- Analyst Decision
- UCAR
- RLMD Hold
- Analyst Count
- UCAR 0
- RLMD 4
- Target Price
- UCAR N/A
- RLMD $4.25
- AVG Volume (30 Days)
- UCAR 67.6K
- RLMD 4.4M
- Earning Date
- UCAR 05-20-2025
- RLMD 05-12-2025
- Dividend Yield
- UCAR N/A
- RLMD N/A
- EPS Growth
- UCAR N/A
- RLMD N/A
- EPS
- UCAR N/A
- RLMD N/A
- Revenue
- UCAR $4,273,899.00
- RLMD N/A
- Revenue This Year
- UCAR N/A
- RLMD N/A
- Revenue Next Year
- UCAR N/A
- RLMD N/A
- P/E Ratio
- UCAR N/A
- RLMD N/A
- Revenue Growth
- UCAR 473.56
- RLMD N/A
- 52 Week Low
- UCAR $2.30
- RLMD $0.24
- 52 Week High
- UCAR $9.43
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- UCAR 56.83
- RLMD 54.34
- Support Level
- UCAR $2.67
- RLMD $0.32
- Resistance Level
- UCAR $3.07
- RLMD $0.40
- Average True Range (ATR)
- UCAR 0.29
- RLMD 0.12
- MACD
- UCAR 0.05
- RLMD -0.01
- Stochastic Oscillator
- UCAR 62.02
- RLMD 31.11
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufactory and sales; battery swapping services and sourcing services. The company as a broker engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.